Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)

1. Guidelines for Diagnosis and Treatment of Cardiovascular Diseases (2006–2007 Joint Working Groups Report).Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008).<i>Circ J</i>2008;72(Suppl IV):1581–1638 (in Japanese).

10.1253/jcj.65.931

3. WolfPA,AbbottRD,KannelWB.Atrial fibrillation as an independent risk factor for stroke: The Framingham Study.<i>Stroke</i>1991;22:983–988.

4. FurbergCD,PsatyBM,ManolioTA,GardinJM,SmithVE,RautaharjuPM.Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).<i>Am J Cardiol</i>1994;74:236–241.

5. MajeedA,MoserK,CarrollK.Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: Analysis of data from the general practice research database.<i>Heart</i>2001;86:284–288.

6. GoAS,HylekEM,PhillipsKA,ChangY,HenaultLE,SelbyJV, et al.Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.<i>JAMA</i>2001;285:2370–2375.

7. HeeringaJ,van der KuipDA,HofmanA,KorsJA,van HerpenG,StrickerBH, et al.Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study.<i>Eur Heart J</i>2006;27:949–953.

8. OhsawaM,OkayamaA,SakataK,KatoK,ItaiK,OnodaT, et al.Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000.<i>J Epidemiol</i>2005;15:194–196.

9. InoueH,FujikiA,OrigasaH,OgawaS,OkumuraK,KubotaI, et al.Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination.<i>Int J Cardiol</i>2009;137:102–107.

10. JeongJH.Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years.<i>J Korean Med Sci</i>2005;20:26–30.

11. ChienKL,SuTC,HsuHC,ChangWT,ChenPC,ChenMF, et al.Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese.<i>Int J Cardiol</i>2010;139:173–180.

12. NieuwlaatR,CapucciA,CammAJ,OlssonSB,AndresenD,DaviesDW, et al.Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation.<i>Eur Heart J</i>2005;26:2422–2434.

13. AtarashiH,InoueH,OkumuraK,YamashitaT,KumagaiN,OrigasaH; J-RHYTHM Registry Investigators.Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry.<i>Circ J</i>2011;75:1328–1333.

14. SuzukiS,YamashitaT,OtsukaT,SagaraK,UejimaT,OikawaY, et al.Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo.<i>J Cardiol</i>2011;58:116–123.

15. BenjaminEJ,LevyD,VaziriSM,D’AgostinoRB,BelangerAJ,WolfPA.Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study.<i>JAMA</i>1994;271:840–844.

16. FujishimaM.Heart disease: Risk factor of cerebral vessel disease.<i>The Journal of Board Certified Member of the Japanese Circulation Society</i>1998;6:19–26 (in Japanese).

17. WatanabeH,TanabeN,WatanabeT,DarbarD,RodenDM,SasakiS, et al.Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study.<i>Circulation</i>2008;117:1255–1260.

18. WatanabeH,WatanabeT,SasakiS,NagaiK,RodenDM,AizawaY.Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study.<i>Am Heart J</i>2009;158:629–636.

19. ChamberlainAM,AgarwalSK,FolsomAR,DuvalS,SolimanEZ,AmbroseM, et al.Smoking and incidence of atrial fibrillation: Results from the Atherosclerosis Risk in Communities (ARIC) study.<i>Heart Rhythm</i>2011;8:1160–1166.

20. PackerDL,BardyGH,WorleySJ,SmithMS,CobbFR,ColemanRE, et al.Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction.<i>Am J Cardiol</i>1986;57:563–570.

21. YamashitaT,MurakawaY,HayamiN,FukuiE,KasaokaY,InoueM, et al.Short-term effects of rapid pacing on mRNA level of voltage-dependent K (+) channels in rat atrium: Electrical remodeling in paroxysmal atrial tachycardia.<i>Circulation</i>2000;101:2007–2014.

22. MaiselWH.Autonomic modulation preceding the onset of atrial fibrillation.<i>J Am Coll Cardiol</i>2003;42:1269–1270.

23. JuliusS,KjeldsenSE,WeberM,BrunnerHR,EkmanS,HanssonL, et al; VALUE trial group.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial.<i>Lancet</i>2004;363:2022–2031.

24. WatanabeH,MaM,WashizukaT,KomuraS,YoshidaT,HosakaY, et al.Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium.<i>Biochem Biophys Res Commun</i>2003;308:439–444.

25. DarbarD,HerronKJ,BallewJD,JahangirA,GershBJ,ShenWK, et al.Familial atrial fibrillation is a genetically heterogeneous disorder.<i>J Am Coll Cardiol</i>2003;41:2185–2192.

26. EllinorPT,LunettaKL,AlbertCM,GlazerNL,RitchieMD,SmithAV, et al.Meta-analysis identifies six new susceptibility loci for atrial fibrillation.<i>Nat Genet</i>2012;44:670–675.

27. KleinGJ,BashoreTM,SellersTD,PritchettEL,SmithWM,GallagherJJ.Ventricular fibrillation in the Wolff-Parkinson-White syndrome.<i>N Engl J Med</i>1979;301:1080–1085.

28. JaïsP,HaïssaguerreM,ShahDC,ChouairiS,GencelL,HociniM, et al.A focal source of atrial fibrillation treated by discrete radiofrequency ablation.<i>Circulation</i>1997;95:572–576.

29. HaïssaguerreM,JaïsP,ShahDC,TakahashiA,HociniM,QuiniouG, et al.Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.<i>N Engl J Med</i>1998;339:659–666.

30. ChenSA,HsiehMH,TaiCT,TsaiCF,PrakashVS,YuWC, et al.Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation.<i>Circulation</i>1999;100:1879–1886.

31. ChenYJ,ChenSA,ChenYC,YehHI,ChanP,ChangMS, et al.Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: Implication in initiation of atrial fibrillation.<i>Circulation</i>2001;104:2849–2854.

32. AroraR,VerheuleS,ScottL,NavarreteA,KatariV,WilsonE, et al.Arrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mapping.<i>Circulation</i>2003;107:1816–1821.

33. AllessieMA,LammersWJEP,BonkeFIM,HollenJ.Experimental evaluation of Moe’s multiple wavelet hypothesis of atrial fibrillation.<i>In</i>: Zipes DP, Jalife J, editors. Cardiac Electrophysiology and Arrhythmias. New York: Grune &amp; Stratton, 1985; 265–275.

34. KumagaiK,KhrestianC,WaldoAL.Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance.<i>Circulation</i>1997;95:511–521.

35. AllessieMA,BonkeFI,SchopmanFJ.Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III: The “leading circle” concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle.<i>Circ Res</i>1977;41:9–18.

36. DillonSM,AllessieMA,UrsellPC,WitAL.Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts.<i>Circ Res</i>1988;63:182–206.

37. PertsovAM,DavidenkoJM,SalomonszR,BaxterWT,JalifeJ.Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle.<i>Circ Res</i>1993;72:631–650.

38. RensmaPL,AllessieMA,LammersWJ,BonkeFI,SchalijMJ.Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.<i>Circ Res</i>1988;62:395–410.

39. WijffelsMC,KirchhofCJ,DorlandR,AllessieMA.Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats.<i>Circulation</i>1995;92:1954–1968.

40. NattelS,LiD.Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation.<i>Circ Res</i>2000;87:440–447.

41. AllessieM,AusmaJ,SchottenU.Electrical, contractile and structural remodeling during atrial fibrillation.<i>Cardiovasc Res</i>2002;54:230–246.

42. LiD,ShinagawaK,PangL,LeungTK,CardinS,WangZ, et al.Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.<i>Circulation</i>2001;104:2608–2614.

43. FoxCS,PariseH,D’AgostinoRB,Lloyd-JonesDM,VasanRS,WangTJ, et al.Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring.<i>JAMA</i>2004;291:2851–2855.

44. ChenYH,XuSJ,BendahhouS,WangXL,WangY,XuWY, et al.KCNQ1 gain-of-function mutation in familial atrial fibrillation.<i>Science</i>2003;299:251–254.

45. ChenLY,BallewJD,HerronKJ,RodehefferRJ,OlsonTM.A common polymorphism in SCN5A is associated with lone atrial fibrillation.<i>Clin Pharmacol Ther</i>2007;81:35–41.

46. GollobMH,JonesDL,KrahnAD,DanisL,GongXQ,ShaoQ, et al.Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.<i>N Engl J Med</i>2006;354:2677–2688.

47. Hodgson-ZingmanDM,KarstML,ZingmanLV,HeubleinDM,DarbarD,HerronKJ, et al.Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.<i>N Engl J Med</i>2008;359:158–165.

48. GudbjartssonDF,ArnarDO,HelgadottirA,GretarsdottirS,HolmH,SigurdssonA, et al.Variants conferring risk of atrial fibrillation on chromosome 4q25.<i>Nature</i>2007;448:353–357.

49. RitchieMD,RowanS,KuceraG,StubblefieldT,BlairM,CarterS, et al.Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation.<i>J Am Coll Cardiol</i>2012;60:1173–1181.

50. GallagherMM,CammAJ.Classification of atrial fibrillation.<i>Pacing Clin Electrophysiol</i>1997;20:1603–1605.

51. FusterV,RydénLE,CannomDS,CrijnsHJ,CurtisAB,EllenbogenKA, et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.<i>Circulation</i>2006;114:e257–e354, doi:10.1161/CIRCULATIONAHA.106.177292.

52. HumphriesKH,KerrCR,ConnollySJ,KleinG,BooneJA,GreenM, et al.New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome.<i>Circulation</i>2001;103:2365–2370.

53. KatoT,YamashitaT,SagaraK,IinumaH,FuLT.Progressive nature of paroxysmal atrial fibrillation: Observations from a 14-year follow-up study.<i>Circ J</i>2004;68:568–572.

54. SakamotoH,OkamotoE,ImatakaK,IekiK,FujiiJ.Prediction of early development of chronic nonrheumatic atrial fibrillation.<i>Jpn Heart J</i>1995;36:191–199.

55. de VosCB,PistersR,NieuwlaatR,PrinsMH,TielemanRG,CoelenRJ, et al.Progression from paroxysmal to persistent atrial fibrillation: Clinical correlates and prognosis.<i>J Am Coll Cardiol</i>2010;55:725–731.

56. Van GelderIC,CrijnsHJ,TielemanRG,BrügemannJ,De KamPJ,GosselinkAT, et al.Chronic atrial fibrillation: Success of serial cardioversion therapy and safety of oral anticoagulation.<i>Arch Intern Med</i>1996;156:2585–2592.

57. HohnloserSH,KuckKH,LilienthalJ.Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial.<i>Lancet</i>2000;356:1789–1794.

58. WyseDG,WaldoAL,DiMarcoJP,DomanskiMJ,RosenbergY,SchronEB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators.A comparison of rate control and rhythm control in patients with atrial fibrillation.<i>N Engl J Med</i>2002;347:1825–1833.

59. Van GelderIC,HagensVE,BoskerHA,KingmaJH,KampO,KingmaT, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group.A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.<i>N Engl J Med</i>2002;347:1834–1840.

60. CarlssonJ,MiketicS,WindelerJ,CuneoA,HaunS,MicusS, et al.Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study.<i>J Am Coll Cardiol</i>2003;41:1690–1696.

61. AndradeJG,ConnollySJ,DorianP,GreenM,HumphriesKH,KleinGJ, et al.Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II).<i>Heart Rhythm</i>2010;7:1171–1177.

62. OgawaS,YamashitaT,YamazakiT,AizawaY,AtarashiH,InoueH, et al; J-RHYTHM Investigators.Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study.<i>Circ J</i>2009;73:242–248.

63. PedersenOD,BaggerH,KoberL,Torp-PedersenC.Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.<i>Circulation</i>1999;100:376–380.

64. DucharmeA,SwedbergK,PfefferMA,Cohen-SolalA,GrangerCB,MaggioniAP, et al.Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.<i>Am Heart J</i>2006;152:86–92.

65. LipGY,BeeversDG.More evidence on blocking the rennin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: Data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).<i>J Hum Hypertens</i>2003;17:747–750.

66. PollickC.Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide.<i>N Engl J Med</i>1982;307:997–999.

67. HamadaM,ShigematsuY,IkedaS,HaraY,OkayamaH,KodamaK, et al.Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.<i>Circulation</i>1997;96:1520–1524.

68. NakazawaH,LythallDA,NohJ,IshikawaN,SuginoK,ItoK, et al.Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation.<i>Eur Heart J</i>2000;21:327–333.

69. EvansW,SwannP.Lone auricular fibrillation.<i>Br Heart J</i>1954;16:189–194.

70. KopeckySL,GershBJ,McGoonMD,ChuCP,IlstrupDM,ChesebroJH, et al.Lone atrial fibrillation in elderly persons: A marker for cardiovascular risk.<i>Arch Intern Med</i>1999;159:1118–1122.

71. FrostL.Lone atrial fibrillation: Good, bad, or ugly?<i>Circulation</i>2007;115:3040–3041.

72. Guidelines for Diagnosis and Treatment of Cardiovascular Diseases (2008 Joint Working Groups Report). Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (available in January 2013, in Japanese).

73. Guidelines for Diagnosis and Treatment of Cardiovascular Diseases (2006–2007 Joint Working Groups Report). Guidelines for Indication and Management of Pregnancy and Delivery in Women with Heart Disease (JCS 2010). http://www.j-circ.or.jp/guideline/pdf/JCS2010niwa.h.pdf (available in January 2013, in Japanese).

74. CammAJ,LipGY,De CaterinaR,SavelievaI,AtarD,HohnloserSH, et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association.<i>Eur Heart J</i>2012;33:2719–2747.

75. CammAJ,KirchhofP,LipGY,SchottenU,SavelievaI,ErnstS, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery.Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).<i>Eur Heart J</i>2010;31:2369–2429.

76. SkanesAC,HealeyJS,CairnsJA,DorianP,GillisAM,McMurtryMS, et al; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee.Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control.<i>Can J Cardiol</i>2012;28:125–136.

77. FurieKL,GoldsteinLB,AlbersGW,KhatriP,NeyensR,TurakhiaMP, et al.Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/American Stroke Association.<i>Stroke</i>2012;43:3442–3453.

78. GageBF,WatermanAD,ShannonW,BoechlerM,RichMW,RadfordMJ.Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation.<i>JAMA</i>2001;285:2864–2870.

79. ConnollySJ,EzekowitzMD,YusufS,EikelboomJ,OldgrenJ,ParekhA, et al; RE-LY Steering Committee and Investigators.Dabigatran versus warfarin in patients with atrial fibrillation.<i>N Engl J Med</i>2009;361:1139–1151.

80. PatelMR,MahaffeyKW,GargJ,PanG,SingerDE,HackeW, et al; ROCKET AF Investigators.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.<i>N Engl J Med</i>2011;365:883–891.

81. GrangerCB,AlexanderJH,McMurrayJJ,LopesRD,HylekEM,HannaM, et al; ARISTOTLE Committees and Investigators.Apixaban versus warfarin in patients with atrial fibrillation.<i>N Engl J Med</i>2011;365:981–992.

82. HoriM,MatsumotoM,TanahashiN,MomomuraS,UchiyamaS,GotoS, et al; J-ROCKET AF study investigators.Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study.<i>Circ J</i>2012;76:2104–2111.

83. LopesRD,Al-KhatibSM,WallentinL,YangH,AnsellJ,BahitMC, et al.Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial.<i>Lancet</i>2012;380:1749–1758.

84. OldgrenJ,AlingsM,DariusH,DienerHC,EikelboomJ,EzekowitzMD, et al; RE-LY Investigators.Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial.<i>Ann Intern Med</i>2011;155:660–667.

85. YamamotoK,IkedaU,FuruhashiK,IrokawaM,NakayamaT,ShimadaK.The coagulation system is activated in idiopathic cardiomyopathy.<i>J Am Coll Cardiol</i>1995;25:1634–1640.

86. NozawaT,InoueH,HiraiT,IwasaA,OkumuraK,LeeJD, et al.D-dimer level influences thromboembolic events in patients with atrial fibrillation.<i>Int J Cardiol</i>2006;109:59–65.

87. Atrial Fibrillation Investigators.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials.<i>Arch Intern Med</i>1994;154:1449–1457.

88. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation.<i>Ann Intern Med</i>1998;128:639–647.

89. OlesenJB,LipGY,HansenML,HansenPR,TolstrupJS,LindhardsenJ, et al.Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study.<i>BMJ</i>2011;342:d124.

90. OlesenJB,FauchierL,LaneDA,TaillandierS,LipGY.Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project.<i>Chest</i>2012;141:147–153.

91. HohnloserSH,PajitnevD,PogueJ,HealeyJS,PfefferMA,YusufS, et al; ACTIVE W Investigators.Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W Substudy.<i>J Am Coll Cardiol</i>2007;50:2156–2161.

92. EikelboomJW,ConnollySJ,BrueckmannM,GrangerCB,KappeteinAP,MackMJ, et al; for the RE-ALIGN Investigators.Dabigatran versus warfarin in patients with mechanical heart valves.<i>N Engl J Med</i>2013;369:1206–1214.

92a. LipGY,NieuwlaatR,PistersR,LaneDA,CrijnsHJ.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation.<i>Chest</i>2010;137:263–272.

93. PistersR,LaneDA,NieuwlaatR,de VosCB,CrijnsHJ,LipGY.A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey.<i>Chest</i>2010;138:1093–1100.

94. EikelboomJW,WallentinL,ConnollySJ,EzekowitzM,HealeyJS,OldgrenJ, et al.Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial.<i>Circulation</i>2011;123:2363–2372.

95. KazuiS,MinematsuK,YamamotoH,SawadaT,YamaguchiT.Predisposing factors to enlargement of spontaneous intracerebral hematoma.<i>Stroke</i>1997;28:2370–2375.

96. KaseCS,MohrJP,CaplanLR.Intracerebral hemorrhage. <i>In</i>: Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PA, editors. Stroke. Pathophysiology, Diagnosis, and Management, 4th edn. Philadelphia: Churchill Livingstone, 2004; 327–376.

97. LeeSH,RyuWS,RohJK.Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage.<i>Neurology</i>2009;72:171–176.

98. HartRG,TonarelliSB,PearceLA.Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas.<i>Stroke</i>2005;36:1588–1593.

99. HartRG,DienerHC,YangS,ConnollySJ,WallentinL,ReillyPA, et al.Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial.<i>Stroke</i>2012;43:1511–1517.

100. ToyodaK,YasakaM,IwadeK,NagataK,KoretsuneY,SakamotoT, et al; Bleeding with Antithrombotic Therapy (BAT) Study Group.Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study.<i>Stroke</i>2008;39:1740–1745.

101. ToyodaK,YasakaM,UchiyamaS,NagaoT,GotohJ,NagataK, et al; Bleeding with Antithrombotic Therapy (BAT) Study Group.Blood pressure levels and bleeding events during antithrombotic therapy: The Bleeding with Antithrombotic Therapy (BAT) Study.<i>Stroke</i>2010;41:1440–1444.

102. YasakaM,MinematsuK,YamaguchiT.Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation.<i>Intern Med</i>2001;40:1183–1188.

103. RosendaalFR,CannegieterSC,van der MeerFJ,BriëtE.A method to determine the optimal intensity of oral anticoagulant therapy.<i>Thromb Haemost</i>1993;69:236–239.

104. SatoH,IshikawaK,KitabatakeA,OgawaS,MaruyamaY,YokotaY, et al.Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.<i>Stroke</i>2006;37:447–451.

105. ArnoldAZ,MickMJ,MazurekRP,LoopFD,TrohmanRG.Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter.<i>J Am Coll Cardiol</i>1992;19:851–855.

106. NaccarelliGV,Dell’OrfanoJT,WolbretteDL,PatelHM,LuckJC.Cost-effective management of acute atrial fibrillation: Role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.<i>Am J Cardiol</i>2000;85:36D–45D.

107. PrystowskyEN,BensonDW,FusterV,HartRG,KayGN,MyerburgRJ, et al.Management of patients with atrial fibrillation: A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association.<i>Circulation</i>1996;93:1262–1277.

108. HartRG,HalperinJL.Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention.<i>Ann Intern Med</i>1999;131:688–695.

109. KleinAL,GrimmRA,MurrayRD,Apperson-HansenC,AsingerRW,BlackIW, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators.Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.<i>N Engl J Med</i>2001;344:1411–1420.

110. EvansIL,SayersMS,GibbonsAJ,PriceG,SnooksH,SugarAW.Can warfarin be continued during dental extraction? Results of a randomized controlled trial.<i>Br J Oral Maxillofac Surg</i>2002;40:248–252.

111. KatzJ,FeldmanMA,BassEB,LubomskiLH,TielschJM,PettyBG, et al.Study of Medical Testing for Cataract Surgery Team. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.<i>Ophthalmology</i>2003;110:1784–1788.

112. FujimotoK,FujishiroM,KatoM,HiguchiK,IwakiriR,SakamotoC, et al.Gastrointestinal Endoscopy guidelines for the management of antithrombotic therapy.<i>Gastroenterol Endosc</i>2012;54:2075–2102 (in Japanese).

113. GiuglianoRP,RuffCT,BraunwaldE,MurphySA,WiviottSD,HalperinJL, et al.Edoxaban versus warfarin in patients with atrial fibrillation.<i>N Engl J Med</i>2013;369:2093–2104.

114. RawlesJM.What is meant by a “controlled” ventricular rate in atrial fibrillation?<i>Br Heart J</i>1990;63:157–161.

115. Van GelderIC,GroenveldHF,CrijnsHJ,TuiningaYS,TijssenJG,AlingsAM, et al; RACE II Investigators.Lenient versus strict rate control in patients with atrial fibrillation.<i>N Engl J Med</i>2010;362:1363–1373.

116. FusterV,RydénLE,CannomDS,CrijnsHJ,CurtisAB,EllenbogenKA, et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.<i>Circulation</i>2011;123:e269–e367, doi:10.1161/CIR.0b013e318214876d.

117. NagaiR,KinugawaK,InoueH,AtarashiH,SeinoY,YamashitaT, et al; J-Land Investigators.Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: Comparison of the ultrashort-acting β1-selective blocker landiolol with digoxin (J-Land Study).<i>Circ J</i>2013;77:908–916.

118. YamashitaT,InoueH.Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: Results of the MAIN-AF study.<i>J Cardiol</i>2013;62:50–57.

119. GalveE,RiusT,BallesterR,ArtazaMA,ArnauJM,García-DoradoD, et al.Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study.<i>J Am Coll Cardiol</i>1996;27:1079–1082.

120. WhitbeckMG,CharnigoRJ,KhairyP,ZiadaK,BaileyAL,ZegarraMM, et al.Increased mortality among patients taking digoxin – analysis from the AFFIRM study.<i>Eur Heart J</i>2013;34:1481–1488.

121. AlboniP,BottoGL,BaldiN,LuziM,RussoV,GianfranchiL, et al.Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach.<i>N Engl J Med</i>2004;351:2384–2391.

122. FalkRH.Proarrhythmia in patients treated for atrial fibrillation or flutter.<i>Ann Intern Med</i>1992;117:141–150.

123. MatsumotoK,SumitaS,IshikawaT,MatsushitaK,KobayashiT,OhkusuY, et al.Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: A case report.<i>J Cardiol</i>2003;42:227–234 (in Japanese).

124. YamashitaT,OgawaS,SatoT,AizawaY,AtarashiH,FujikiA, et al; J-BAF Investigators.Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: A multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).<i>Circ J</i>2009;73:1020–1027.

125. YamaseM,NakazatoY,DaidaH.Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: A randomised trial.<i>Heart</i>2012;98:1067–1071.

126. ShigaT,SuzukiA,NaganumaM,HosakaF,ShodaM,HagiwaraN.Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil.<i>Circ J</i>2011;75:1334–1342.

127. RoyD,TalajicM,DorianP,ConnollyS,EisenbergMJ,GreenM, et al; Canadian Trial of Atrial Fibrillation Investigators.Amiodarone to prevent recurrence of atrial fibrillation.<i>N Engl J Med</i>2000;342:913–920.

128. WachtellK,LehtoM,GerdtsE,OlsenMH,HornestamB,DahlöfB, et al.Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.<i>J Am Coll Cardiol</i>2005;45:712–719.

129. VermesE,TardifJC,BourassaMG,RacineN,LevesqueS,WhiteM, et al.Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.<i>Circulation</i>2003;107:2926–2931.

130. MaggioniAP,LatiniR,CarsonPE,SinghSN,BarleraS,GlazerR, et al; Val-HeFT Investigators.Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT).<i>Am Heart J</i>2005;149:548–557.

131. KühlkampV,SchirdewanA,StanglK,HombergM,PlochM,BeckOA.Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study.<i>J Am Coll Cardiol</i>2000;36:139–146.

132. AtarashiH,InoueH,HiejimaK,HayakawaH; The PSTAF investigators.Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation).<i>Am J Cardiol</i>1996;78:694–697.

133. CapucciA,LenziT,BorianiG,TrisolinoG,BinettiN,CavazzaM, et al.Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension.<i>Am J Cardiol</i>1992;70:69–72.

134. CapucciA,BorianiG,BottoGL,LenziT,RubinoI,FalconeC, et al.Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide.<i>Am J Cardiol</i>1994;74:503–505.

135. ShimadaM,YokozukaH,InoueS,KoyamaT,KodamaH,SuzukiY, et al.Pill-in-the pocket approach for paroxysmal atrial fibrillation by cibenzoline succinate.<i>Jpn J Electrocardiology</i>2006;26:710–719 (in Japanese).

136. KumagaiK,NakashimaH,UrataH,GondoN,ArakawaK,SakuK.Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.<i>J Am Coll Cardiol</i>2003;41:2197–2204.

137. NakashimaH,KumagaiK.Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model.<i>Circ J</i>2007;71:1977–1982.

138. SchaerBA,SchneiderC,JickSS,ConenD,OsswaldS,MeierCR.Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study.<i>Ann Intern Med</i>2010;152:78–84.

139. HeckbertSR,WigginsKL,GlazerNL,DublinS,PsatyBM,SmithNL, et al.Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population.<i>Am J Hypertens</i>2009;22:538–544.

140. DisertoriM,LatiniR,BarleraS,FranzosiMG,StaszewskyL,MaggioniAP, et al; GISSI-AF Investigators.Valsartan for prevention of recurrent atrial fibrillation.<i>N Engl J Med</i>2009;360:1606–1617.

141. YamashitaT,InoueH,OkumuraK,KodamaI,AizawaY,AtarashiH, et al; J-RHYTHM II Investigators.Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).<i>Europace</i>2011;13:473–479.

142. YusufS,HealeyJS,PogueJ,ChrolaviciusS,FlatherM,HartRG, et al; ACTIVE I Investigators.Irbesartan in patients with atrial fibrillation.<i>N Engl J Med</i>2011;364:928–938.

143. KumagaiK,NakashimaH,SakuK.The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.<i>Cardiovasc Res</i>2004;62:105–111.

144. SavelievaI,KourliourosA,CammJ.Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: Review of evidence and clinical relevance.<i>Naunyn Schmiedebergs Arch Pharmacol</i>2010;381:1–13.

145. PattiG,ChelloM,CanduraD,PasceriV,D’AmbrosioA,CovinoE, et al.Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.<i>Circulation</i>2006;114:1455–1461.

146. AlmrothH,HöglundN,BomanK,EnglundA,JensenS,KjellmanB, et al.Atorvastatin and persistent atrial fibrillation following cardioversion: A randomized placebo-controlled multicentre study.<i>Eur Heart J</i>2009;30:827–833.

147. FauchierL,PierreB,de LabriolleA,GrimardC,ZannadN,BabutyD.Antiarrhythmic effect of statin therapy and atrial fibrillation: A meta-analysis of randomized controlled trials.<i>J Am Coll Cardiol</i>2008;51:828–835.

148. PapponeC,RosanioS,OretoG,TocchiM,GugliottaF,VicedominiG, et al.Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation.<i>Circulation</i>2000;102:2619–2628.

149. OuyangF,BänschD,ErnstS,SchaumannA,HachiyaH,ChenM, et al.Complete isolation of left atrium surrounding the pulmonary veins: New insights from the double-Lasso technique in paroxysmal atrial fibrillation.<i>Circulation</i>2004;110:2090–2096.

150. OralH,PapponeC,ChughA,GoodE,BogunF,PelosiFJr, et al.Circumferential pulmonary vein ablation for chronic atrial fibrillation.<i>N Engl J Med</i>2006;354:934–941.

151. NademaneeK,McKenzieJ,KosarE,SchwabM,SunsaneewitayakulB,VasavakulT, et al.A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate.<i>J Am Coll Cardiol</i>2004;43:2044–2053.

152. ScanavaccaM,PisaniCF,HachulD,LaraS,HardyC,DarrieuxF, et al.Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation.<i>Circulation</i>2006;114:876–885.

153. HociniM,JaïsP,SandersP,TakahashiY,RotterM,RostockT, et al.Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: A prospective randomized study.<i>Circulation</i>2005;112:3688–3696.

154. OralH,KnightBP,TadaH,OzaydinM,ChughA,HassanS, et al.Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.<i>Circulation</i>2002;105:1077–1081.

155. WazniOM,MarroucheNF,MartinDO,VermaA,BhargavaM,SalibaW, et al.Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial.<i>JAMA</i>2005;293:2634–2640.

156. CappatoR,CalkinsH,ChenSA,DaviesW,IesakaY,KalmanJ, et al.Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.<i>Circulation</i>2005;111:1100–1105.

157. OralH,ChughA,GoodE,IgicP,ElmouchiD,TschoppDR, et al.Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation.<i>Heart Rhythm</i>2005;2:1165–1172.

158. OralH,ChughA,OzaydinM,GoodE,FortinoJ,SankaranS, et al.Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.<i>Circulation</i>2006;114:759–765.

159. Di BiaseL,FahmyTS,WazniOM,BaiR,PatelD,LakkireddyD, et al.Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: Clinical implications after long-term follow-up.<i>J Am Coll Cardiol</i>2006;48:2493–2499.

160. CummingsJE,SchweikertRA,SalibaWI,BurkhardtJD,KilikaslanF,SaadE, et al.Brief communication: Atrial-esophageal fistulas after radiofrequency ablation.<i>Ann Intern Med</i>2006;144:572–574.

161. SacherF,MonahanKH,ThomasSP,DavidsonN,AdragaoP,SandersP, et al.Phrenic nerve injury after atrial fibrillation catheter ablation: Characterization and outcome in a multicenter study.<i>J Am Coll Cardiol</i>2006;47:2498–2503.

162. CappatoR,CalkinsH,ChenSA,DaviesW,IesakaY,KalmanJ, et al.Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.<i>Circ Arrhythm Electrophysiol</i>2010;3:32–38.

163. WoodMA,Brown-MahoneyC,KayGN,EllenbogenKA.Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis.<i>Circulation</i>2000;101:1138–1144.